| Autor: |
Chahal, Karn, Glass, Matthew, Falk, Jamie, Singer, Alexander, Leong, Christine |
| Předmět: |
|
| Zdroj: |
Health Science Reports; Dec2023, Vol. 6 Issue 12, p1-13, 13p |
| Abstrakt: |
Background and Aims: Communicating information about the risks and benefits of benzodiazepines so that it is meaningful to the patient has not been previously described. This study aims to determine patient preferences regarding information received before initiating a benzodiazepine. Methods: An online survey was distributed through social media and advertisements to Canadians ≥18 years old over a 6‐month period (May–Oct 2022) to collect participant's rating of importance of statements and factors about the risk and benefits of benzodiazepines before initiating treatment using a 10‐point Likert‐type scale. Treatment preferences based on efficacy and risk information were also elicited. The survey was developed and pilot‐tested in collaboration with an advisory committee of individuals with lived and living experience with benzodiazepine use. Results: Thirty‐seven participants responded to the survey (mean age 30 years old, 81.1% identified as female). The majority of respondents had a history of anxiety (83.8%) or insomnia (32.4%), and 10 (27.0%) respondents had used a benzodiazepine. Patient counseling related to withdrawal symptoms of benzodiazepines, risk of harm in combination with other sedating agents, risk of physical and psychological dependence, and risk of effects on cognition were rated high in the importance of receiving this information before starting a benzodiazepine relative to efficacy endpoints, such as improvement in sleep parameters. When provided with information about the chance of efficacy and risk of harm, 100% would have selected cognitive behavioral therapy as the best treatment option. The most frequently reported source of medication information where patients have sought information was from the internet (25.0%), followed by doctors (21.9%) and pharmacists (18.8%). Conclusions: This study identified patient important factors and statements viewed as important to communicate before initiating a benzodiazepine. The findings of this survey study will help inform decision‐making when considering treatment options for managing anxiety or insomnia. Key points: This study revealed that there may be gaps in knowledge about the expected duration of benzodiazepine use for anxiety or insomnia with only half of participants reporting that they received benzodiazepine counseling from a healthcare provider before starting their benzodiazepine.Participants placed high importance on receiving information related to withdrawal symptoms of benzodiazepines, risk of harm in combination with other sedating agents, risk of physical and psychological dependence, and risk of effects on memory and cognition before starting a benzodiazepine. A maximum of 10 counseling points on average was deemed acceptable within one counseling session to address the safety and efficacy of benzodiazepines before initiation.When provided with the opportunity to review the risk–benefit profiles of treatment options, participants were more likely to select cognitive behavioral therapy over benzodiazepines or no treatment.Policies that provide incentives to support the time to provide information on the risk and benefits of benzodiazepines could have an influence on helping patients and healthcare providers make an informed decision about treatment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text